Outcome of patients with metastatic sarcomatoid renal cell carcinoma: Results from the international metastatic renal cell carcinoma database consortium

Christos E. Kyriakopoulos; Namita Chittoria; Toni K. Choueiri; Nils Kroeger; Jae Lyun Lee; Sandy Srinivas; Jennifer J. Knox; Georg A. Bjarnason; Scott D. Ernst; Lori A. Wood; Ulka N. Vaishampayan; Neeraj Agarwal; Sumanta K. Pal; Ravindran Kanesvaran; Sun Young Rha; Takeshi Yuasa; Frede Donskov; Scott A. North; Daniel Y. Heng; Brian I. Rini

doi:10.1016/j.clgc.2014.08.011

Outcome of patients with metastatic sarcomatoid renal cell carcinoma: Results from the international metastatic renal cell carcinoma database consortium

Christos E. Kyriakopoulos, Namita Chittoria, Toni K. Choueiri, Nils Kroeger, Jae Lyun Lee, Sandy Srinivas, Jennifer J. Knox, Georg A. Bjarnason, Scott D. Ernst, Lori A. Wood, Ulka N. Vaishampayan, Neeraj Agarwal, Sumanta K. Pal, Ravindran Kanesvaran, Sun Young Rha, Takeshi Yuasa, Frede Donskov, Scott A. North, Daniel Y. Heng, Brian I. Rini

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

73 Citations (Scopus)

Abstract

Background Sarcomatoid renal cell carcinoma is associated with poor prognosis. Data regarding outcome in the targeted therapy era are lacking. Patients and Methods Clinical, prognostic, and treatment parameters in metastatic renal cell carcinoma patients with and without sarcomatoid histology treated with targeted therapy were retrospectively analyzed. Results Two thousand two hundred eighty-six patients were identified (sRCC: n = 230 and non-sRCC: n = 2056). sRCC patients had significantly worse IMDC prognostic criteria compared with non-sRCC (11% vs. 19% favorable risk; 49% vs. 57% intermediate risk, and 40% vs. 24% poor risk; P <.0001). Time from original diagnosis to relapse (excluding synchronous metastatic disease) was shorter in the sRCC group (18.8 vs. 42.9 months; P <.0001). There was no significant difference in the incidence of central nervous system metastases (6%-8%) or underlying clear cell histology (87%-88%). More than 93% of patients received VEGF inhibitors as first-line therapy; objective response was less common in sRCC whereas primary refractory disease was more common (21% vs. 26% and 43% vs. 21%; P <.0001, for both). sRCC patients had significantly less use of second- (P =.018) and third-line (P <.0001) systemic therapy. The median progression-free survival (PFS)/overall survival (OS) was 4.5/10.4 months in sRCC patients and 7.8/22.5 months in non-sRCC patients (P <.0001 for both). Sarcomatoid histology was associated with a significantly worse PFS and OS after adjusting for individual IMDC risk factors in multivariable analysis (hazard ratio, 1.5; P <.0001 for both). Conclusion Patients with sRCC have a shorter time to relapse, worse baseline prognostic criteria, and worse clinical outcome with targeted therapy. Additional insight into the biology of sRCC is needed to develop alternative therapeutics.

Original language	English
Pages (from-to)	e79-e85
Journal	Clinical Genitourinary Cancer
Volume	13
Issue number	2
DOIs	https://doi.org/10.1016/j.clgc.2014.08.011
Publication status	Published - 2015 Apr 1

Bibliographical note

Funding Information:
Toni K. Choueiri has received research funding from Pfizer and has an advisory role at Aveo, Bayer, Genentech, GlaxoSmithKline, Novartis, and Pfizer. Jae-Lyun Lee has received honoraria from Bayer, Novartis, and Pfizer, and has received research funding from Bayer. Jennifer J. Knox has been a consultant and has played an advisory role at Aveo and has received research funding from Pfizer. Georg A. Bjarnason has been a consultant and has played an advisory role at Pfizer and has received honoraria and research funding from Pfizer. Lori A. Wood has been a consultant and has played an advisory role at Pfizer and has received research funding from Pfizer, Novartis, and GlaxoSmithKline. Frede Donskov has received research funding from Novartis and GlaxoSmithKline. Daniel Y. Heng is a consultant and has an advisory role at Bayer/Onyx, Novartis, and Pfizer. Brian I. Rini has an advisory role at Pfizer and has received research funding from Pfizer. The remaining authors have stated that they have no conflicts of interest.

Publisher Copyright:
© 2015 Elsevier Inc. All rights reserved.

All Science Journal Classification (ASJC) codes

Oncology
Urology

Access to Document

10.1016/j.clgc.2014.08.011

Cite this

Kyriakopoulos, C. E., Chittoria, N., Choueiri, T. K., Kroeger, N., Lee, J. L., Srinivas, S., Knox, J. J., Bjarnason, G. A., Ernst, S. D., Wood, L. A., Vaishampayan, U. N., Agarwal, N., Pal, S. K., Kanesvaran, R., Rha, S. Y., Yuasa, T., Donskov, F., North, S. A., Heng, D. Y., & Rini, B. I. (2015). Outcome of patients with metastatic sarcomatoid renal cell carcinoma: Results from the international metastatic renal cell carcinoma database consortium. Clinical Genitourinary Cancer, 13(2), e79-e85. https://doi.org/10.1016/j.clgc.2014.08.011

@article{45a3bd1eb438415d867a2f1f19953977,

title = "Outcome of patients with metastatic sarcomatoid renal cell carcinoma: Results from the international metastatic renal cell carcinoma database consortium",

abstract = "Background Sarcomatoid renal cell carcinoma is associated with poor prognosis. Data regarding outcome in the targeted therapy era are lacking. Patients and Methods Clinical, prognostic, and treatment parameters in metastatic renal cell carcinoma patients with and without sarcomatoid histology treated with targeted therapy were retrospectively analyzed. Results Two thousand two hundred eighty-six patients were identified (sRCC: n = 230 and non-sRCC: n = 2056). sRCC patients had significantly worse IMDC prognostic criteria compared with non-sRCC (11% vs. 19% favorable risk; 49% vs. 57% intermediate risk, and 40% vs. 24% poor risk; P <.0001). Time from original diagnosis to relapse (excluding synchronous metastatic disease) was shorter in the sRCC group (18.8 vs. 42.9 months; P <.0001). There was no significant difference in the incidence of central nervous system metastases (6%-8%) or underlying clear cell histology (87%-88%). More than 93% of patients received VEGF inhibitors as first-line therapy; objective response was less common in sRCC whereas primary refractory disease was more common (21% vs. 26% and 43% vs. 21%; P <.0001, for both). sRCC patients had significantly less use of second- (P =.018) and third-line (P <.0001) systemic therapy. The median progression-free survival (PFS)/overall survival (OS) was 4.5/10.4 months in sRCC patients and 7.8/22.5 months in non-sRCC patients (P <.0001 for both). Sarcomatoid histology was associated with a significantly worse PFS and OS after adjusting for individual IMDC risk factors in multivariable analysis (hazard ratio, 1.5; P <.0001 for both). Conclusion Patients with sRCC have a shorter time to relapse, worse baseline prognostic criteria, and worse clinical outcome with targeted therapy. Additional insight into the biology of sRCC is needed to develop alternative therapeutics.",

author = "Kyriakopoulos, {Christos E.} and Namita Chittoria and Choueiri, {Toni K.} and Nils Kroeger and Lee, {Jae Lyun} and Sandy Srinivas and Knox, {Jennifer J.} and Bjarnason, {Georg A.} and Ernst, {Scott D.} and Wood, {Lori A.} and Vaishampayan, {Ulka N.} and Neeraj Agarwal and Pal, {Sumanta K.} and Ravindran Kanesvaran and Rha, {Sun Young} and Takeshi Yuasa and Frede Donskov and North, {Scott A.} and Heng, {Daniel Y.} and Rini, {Brian I.}",

note = "Funding Information: Toni K. Choueiri has received research funding from Pfizer and has an advisory role at Aveo, Bayer, Genentech, GlaxoSmithKline, Novartis, and Pfizer. Jae-Lyun Lee has received honoraria from Bayer, Novartis, and Pfizer, and has received research funding from Bayer. Jennifer J. Knox has been a consultant and has played an advisory role at Aveo and has received research funding from Pfizer. Georg A. Bjarnason has been a consultant and has played an advisory role at Pfizer and has received honoraria and research funding from Pfizer. Lori A. Wood has been a consultant and has played an advisory role at Pfizer and has received research funding from Pfizer, Novartis, and GlaxoSmithKline. Frede Donskov has received research funding from Novartis and GlaxoSmithKline. Daniel Y. Heng is a consultant and has an advisory role at Bayer/Onyx, Novartis, and Pfizer. Brian I. Rini has an advisory role at Pfizer and has received research funding from Pfizer. The remaining authors have stated that they have no conflicts of interest. Publisher Copyright: {\textcopyright} 2015 Elsevier Inc. All rights reserved.",

year = "2015",

month = apr,

day = "1",

doi = "10.1016/j.clgc.2014.08.011",

language = "English",

volume = "13",

pages = "e79--e85",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

publisher = "Elsevier",

number = "2",

}

Kyriakopoulos, CE, Chittoria, N, Choueiri, TK, Kroeger, N, Lee, JL, Srinivas, S, Knox, JJ, Bjarnason, GA, Ernst, SD, Wood, LA, Vaishampayan, UN, Agarwal, N, Pal, SK, Kanesvaran, R, Rha, SY, Yuasa, T, Donskov, F, North, SA, Heng, DY & Rini, BI 2015, 'Outcome of patients with metastatic sarcomatoid renal cell carcinoma: Results from the international metastatic renal cell carcinoma database consortium', Clinical Genitourinary Cancer, vol. 13, no. 2, pp. e79-e85. https://doi.org/10.1016/j.clgc.2014.08.011

Outcome of patients with metastatic sarcomatoid renal cell carcinoma: Results from the international metastatic renal cell carcinoma database consortium. / Kyriakopoulos, Christos E.; Chittoria, Namita; Choueiri, Toni K. et al.
In: Clinical Genitourinary Cancer, Vol. 13, No. 2, 01.04.2015, p. e79-e85.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Outcome of patients with metastatic sarcomatoid renal cell carcinoma

T2 - Results from the international metastatic renal cell carcinoma database consortium

AU - Kyriakopoulos, Christos E.

AU - Chittoria, Namita

AU - Choueiri, Toni K.

AU - Kroeger, Nils

AU - Lee, Jae Lyun

AU - Srinivas, Sandy

AU - Knox, Jennifer J.

AU - Bjarnason, Georg A.

AU - Ernst, Scott D.

AU - Wood, Lori A.

AU - Vaishampayan, Ulka N.

AU - Agarwal, Neeraj

AU - Pal, Sumanta K.

AU - Kanesvaran, Ravindran

AU - Rha, Sun Young

AU - Yuasa, Takeshi

AU - Donskov, Frede

AU - North, Scott A.

AU - Heng, Daniel Y.

AU - Rini, Brian I.

N1 - Funding Information: Toni K. Choueiri has received research funding from Pfizer and has an advisory role at Aveo, Bayer, Genentech, GlaxoSmithKline, Novartis, and Pfizer. Jae-Lyun Lee has received honoraria from Bayer, Novartis, and Pfizer, and has received research funding from Bayer. Jennifer J. Knox has been a consultant and has played an advisory role at Aveo and has received research funding from Pfizer. Georg A. Bjarnason has been a consultant and has played an advisory role at Pfizer and has received honoraria and research funding from Pfizer. Lori A. Wood has been a consultant and has played an advisory role at Pfizer and has received research funding from Pfizer, Novartis, and GlaxoSmithKline. Frede Donskov has received research funding from Novartis and GlaxoSmithKline. Daniel Y. Heng is a consultant and has an advisory role at Bayer/Onyx, Novartis, and Pfizer. Brian I. Rini has an advisory role at Pfizer and has received research funding from Pfizer. The remaining authors have stated that they have no conflicts of interest. Publisher Copyright: © 2015 Elsevier Inc. All rights reserved.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background Sarcomatoid renal cell carcinoma is associated with poor prognosis. Data regarding outcome in the targeted therapy era are lacking. Patients and Methods Clinical, prognostic, and treatment parameters in metastatic renal cell carcinoma patients with and without sarcomatoid histology treated with targeted therapy were retrospectively analyzed. Results Two thousand two hundred eighty-six patients were identified (sRCC: n = 230 and non-sRCC: n = 2056). sRCC patients had significantly worse IMDC prognostic criteria compared with non-sRCC (11% vs. 19% favorable risk; 49% vs. 57% intermediate risk, and 40% vs. 24% poor risk; P <.0001). Time from original diagnosis to relapse (excluding synchronous metastatic disease) was shorter in the sRCC group (18.8 vs. 42.9 months; P <.0001). There was no significant difference in the incidence of central nervous system metastases (6%-8%) or underlying clear cell histology (87%-88%). More than 93% of patients received VEGF inhibitors as first-line therapy; objective response was less common in sRCC whereas primary refractory disease was more common (21% vs. 26% and 43% vs. 21%; P <.0001, for both). sRCC patients had significantly less use of second- (P =.018) and third-line (P <.0001) systemic therapy. The median progression-free survival (PFS)/overall survival (OS) was 4.5/10.4 months in sRCC patients and 7.8/22.5 months in non-sRCC patients (P <.0001 for both). Sarcomatoid histology was associated with a significantly worse PFS and OS after adjusting for individual IMDC risk factors in multivariable analysis (hazard ratio, 1.5; P <.0001 for both). Conclusion Patients with sRCC have a shorter time to relapse, worse baseline prognostic criteria, and worse clinical outcome with targeted therapy. Additional insight into the biology of sRCC is needed to develop alternative therapeutics.

AB - Background Sarcomatoid renal cell carcinoma is associated with poor prognosis. Data regarding outcome in the targeted therapy era are lacking. Patients and Methods Clinical, prognostic, and treatment parameters in metastatic renal cell carcinoma patients with and without sarcomatoid histology treated with targeted therapy were retrospectively analyzed. Results Two thousand two hundred eighty-six patients were identified (sRCC: n = 230 and non-sRCC: n = 2056). sRCC patients had significantly worse IMDC prognostic criteria compared with non-sRCC (11% vs. 19% favorable risk; 49% vs. 57% intermediate risk, and 40% vs. 24% poor risk; P <.0001). Time from original diagnosis to relapse (excluding synchronous metastatic disease) was shorter in the sRCC group (18.8 vs. 42.9 months; P <.0001). There was no significant difference in the incidence of central nervous system metastases (6%-8%) or underlying clear cell histology (87%-88%). More than 93% of patients received VEGF inhibitors as first-line therapy; objective response was less common in sRCC whereas primary refractory disease was more common (21% vs. 26% and 43% vs. 21%; P <.0001, for both). sRCC patients had significantly less use of second- (P =.018) and third-line (P <.0001) systemic therapy. The median progression-free survival (PFS)/overall survival (OS) was 4.5/10.4 months in sRCC patients and 7.8/22.5 months in non-sRCC patients (P <.0001 for both). Sarcomatoid histology was associated with a significantly worse PFS and OS after adjusting for individual IMDC risk factors in multivariable analysis (hazard ratio, 1.5; P <.0001 for both). Conclusion Patients with sRCC have a shorter time to relapse, worse baseline prognostic criteria, and worse clinical outcome with targeted therapy. Additional insight into the biology of sRCC is needed to develop alternative therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=84924619957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924619957&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2014.08.011

DO - 10.1016/j.clgc.2014.08.011

M3 - Article

C2 - 25450036

AN - SCOPUS:84924619957

SN - 1558-7673

VL - 13

SP - e79-e85

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

IS - 2

ER -

Outcome of patients with metastatic sarcomatoid renal cell carcinoma: Results from the international metastatic renal cell carcinoma database consortium

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this